1. Immune landscape evaluation of NSCLC clinical samples
- Author
-
Carsten Gram Hanson, Maria Planck, Åslaug Helland, Georgios Mermelekas, Taner Arslan, Lukas M. Orre, Husen M. Umer, Fabio Socciarelli, Vilde Drageset Haakensen, David Tamborero, Mohammad Pirmoradian, Sofi Isaksson, Olena Berkovska, Richard Cunningham, Odd Terje Brustugun, Yanbo Pan, Rui M. Branca, Henrik J. Johansson, Hans Brunnström, Mats Jonsson, Janne Lehtiö, Anna Karlsson, Mattias Aine, Ioannis Siavelis, Elsa Arbajian, Hassan Foroughi Asl, Marija Kotevska, Krishna Pinganksha Purohit, and Johan Staaf
- Subjects
Immune system ,business.industry ,Immunology ,Medicine ,business - Abstract
The associated publication reports proteogenomic analysis of non-small cell lung cancer, where we identified molecular subtypes with distinct immune evasion mechanisms and therapeutic targets, and validated our classification method in separate clinical cohorts. This protocol describes histological, tertiary lymphoid structure (TLS), and immunohistochemical evaluation of clinical samples. Specifically, immunohistochemistry was performed for PD-L1, CD3, and CD8 on tumor microarrays (TMAs) derived from formalin-fixed paraffin embedded (FFPE) samples.
- Published
- 2021
- Full Text
- View/download PDF